Consensus Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
8.59 ^USD	-2.28%		+3.00%	-12.88%

Apr. 18	Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	MT
Apr. 16	Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	MT

Evolution of the average Target Price on Recursion Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d1d1f0.JY0uHvG6NA___gHV3Jw1GJXOEOhsl44fMB8k2yMmUaU.ZttbdKjXVValk3i37uhiVd_jSa4Z4dsvR3pul3R5EuBp71REmPwHX7K0Yg~1dcd84e9bddff548e7ac20f47d6e4795

Analyst Recommendations on Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	Apr. 18	MT
Needham Raises Price Target on Recursion Pharmaceuticals to $17 From $15, Maintains Buy Rating	Feb. 28	MT
TD Cowen Starts Recursion Pharmaceuticals With Market Perform Rating	Jan. 26	MT
JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating	Nov. 13	MT
Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating	Nov. 10	MT
KeyBanc Adjusts Price Target on Recursion Pharmaceuticals to $15 From $12, Maintains Overweight Rating	23-07-13	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $35 From $33, Maintains Buy Rating	23-07-13	MT
Morgan Stanley Lifts Price Target on Recursion Pharmaceuticals to $11 From $8 Amid NVIDIA Partnership, Keeps Equalweight Rating	23-07-13	MT
Keybanc Adjusts Price Target on Recursion Pharmaceuticals to $12 From $20, Keeps Overweight Rating	23-05-09	MT
Needham Starts Recursion Pharmaceuticals at Buy With $17 Price Target	23-03-16	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $33 From $42, Maintains Buy Rating	23-02-02	MT
SVB Securities Adjusts Price Target on Recursion Pharmaceuticals to $8 From $9, Maintains Market Perform Rating	23-01-23	MT
Berenberg Discover AI Seminar	22-11-28	FA
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $42 From $38, Maintains Buy Rating	22-11-16	MT
Goldman Sachs Adjusts Price Target on Recursion Pharmaceuticals to $9 From $8, Maintains Neutral Rating	22-11-09	MT
KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target	22-09-16	MT
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum	22-08-18	PR
Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neutral Rating	22-08-11	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals' Price Target to $38 From $36, Maintains Buy Rating	22-06-22	MT
Goldman Sachs Lowers Recursion Pharmaceuticals' Price Target to $7 From $9, Neutral Rating Kept	22-05-24	MT
Berenberg Discover AI Seminar	22-04-25	FA
BofA Securities Downgrades Recursion Pharmaceuticals to Neutral from Buy	22-04-18	MT
Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $10 from $32, Keeps Neutral Rating	22-03-24	MT
SVB Leerink Downgrades Recursion Pharmaceuticals to Market Perform from Outperform, Adjusts Price Target to $10 from $32	22-03-04	MT
Berenberg Bank Trims Recursion Pharmaceuticals' Price Target to $36 From $37 on Delayed REC-3599 Timeline; Buy Rating Kept	22-03-04	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.59 USD

Average target price

13 USD

Spread / Average Target

+51.34%

High Price Target

17 USD

Spread / Highest target

+97.90%

Low Price Target

10 USD

Spread / Lowest Target

+16.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Recursion Pharmaceuticals, Inc.

Needham & Co.
TD Cowen
JPMorgan Chase
KeyBanc Capital Markets
Morgan Stanley
Berenberg Bank
SVB Securities LLC
Goldman Sachs
BofA Securities
SVB Leerink
J.P. Morgan Chase

Ratings for Recursion Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar